Metin Kılınç, Selma Yaman, Nursima Çukadar, Furkan Baran, Fatih Burak Uyanık, Tufan Mert

Monoklonal antikorlardan bevacizumab'ın deneysel inflamatuar ağrı modelinde antianjiyogenik etkisi

Amaç: Bu çalışmada, deneysel inflamatuar modelinde(Carrageenan kullanılarak meydana getirilen) sistemik(intraperitoneal: IP) ve lokal (intraplantar: IPL) olarakuygulanan bevacizumab’ın muhtemel anti-nosiseptif, antiinflamatuar ve anti-ödem etkilerinin araştırılmasıamaçlanmıştır.Gereç ve Yöntem: Sağlıklı ve Carrageenan (CAR)kullanılarak gerçekleştirilen inflamatuar ağrılı sıçanlarınduysal fonksiyonları termal plantar test (hiperaljezi için),dinamik plantar estesiometre (allodini için) kullanılarak,farklı dozlarda bevacizumab’ın sistemik veya lokal antihipernosiseptif etkileri, pençe kütleleri ölçülerek de antiödem etkileri değerlendirildi. Biyokimyasal analizler içinsıçan pençelerinden alınan örnekler kullanıldı.Bulgular: Kontrol olarak kullanılan sağlıklı sıçanlardalokal (intraplantar: IPL) veya sistemik (intraperitoneal: IP)bevacizumab uygulamasının nörobiyofizik testlerde termallatans veya mekanik eşik parametrelerinde herhangi birdeğişime neden olmadığı görüldü. CAR uygulamasımekanik eşik ve termal latans parametresinde düşüşlere vepençe kütlesinde artışa neden oldu.Sonuç: Çalışmalarımızda, bevacizumab’ın özelliklesistemik uygulamalarının daha fazla anti-hiperaljezik veanti-allodinik etkiler gösterebileceği belirlendi. CARuygulaması sonrası ortaya çıkan hiperaljezi, ağrılı biruyaranın kullanıldığı termal latans ölçümleriyle belirlendi.Ortaya çıkan hiperaljezi, sistemik bevacizumab tarafındanetkili bir şekilde uzun süreli baskılandı

Antiangiogenic effect of bevacizumab in monoclonal antibodies in experimental inflammatory pain model

Purpose: This study aimed to investigate the possible antinociceptive, anti-inflammatory and anti-edema effects of systemic (intaperitoneal) and local (intraplantar) bevacizumab in the experimental inflammation model (introduced with Carrageenan). Materials and Methods: Sensory functions of rats with inflammatory pain (using Carrageenan (CAR)), performed using healthy and CAR, systemically or locally antihypernaphyseceptive effects of bevacizumab at different doses, using thermal plantar test (for hyperalgesia), dynamic plantaraesthesiometer (for allodynia) anti-edema effects were evaluated by measuring paw masses. Results: The application of local intraplantar (IPL) or intraperitoneal (IP) bevacizumab in healthy rats used as controls in the studies did not cause any change in the thermal latency or mechanical threshold parameters in neurobiophysical tests. CAR application caused a decrease in mechanical threshold and thermal latency parameters and an increase in paw mass. Conclusion: Systemic applications of bevacizumab may show more anti-hyperalgesic and anti-allodinic effects. Hyperalgesia pain following CAR application was determined by thermal latency measurements using a stimulus. The resulting hyperalgesia was effectively suppressed by systemic bevacizumab for a long time.

PDF

___

1. Loeser JD, Melzack R. Pain: an overview. Lancet. 1999;353:1607-9.
2. Bars DL, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001;53:597–652.
3. Steeds CE. The anatomy and physiology of pain. Surgery (Oxford). 2009;507-511.
4. Andrew D, Greenspan JD. Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol. 1999;82:2649–56.
5. Fechoa K, Nackley AG, Wu Y, Maixner W. Basal and carrageenan-induced pain behavior in Sprague– Dawley, Lewis and Fischer rats. Physiol Behav. 2005;85:177-86.
6. Türk Farmakoloji Derneği XXII. Eğitim Toplantısı Doğu Akdeniz Farmakoloji Topluluğu (DAFT) İşbirliğiyle İnflamasyon ve Ağrı 29 Mayıs 2015 Çukurova Üniversitesi Akif Kansu Toplantı Salonu, Balcalı, Adana.
7. Aydın ON. Ağrı ve ağrı mekanizmalarına güncel bakış. ADÜ Tıp Fakültesi Dergisi. 2002;3:37-48.
8. Kayhan Z. Klinik Anestezi. 2. Baskı İstanbul, Logos Yayıncılık, 1997
9. Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth. 2001;3-11.
10. Güneş Y, Mert T, Özcengiz D, Günay İ. Ağrının iletilmesinde N-metil D-aspartat reseptörlerinin rolü. Cukurova Medical Journal. 2012;37:9-16.
11. Martin TJ, Eisenach JC. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther. 2001;299:811-7.
12. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev. 2003; 55:1-20.
13. Hargreaves K, Dubner R, Broun F, Flores C, Joris J. A New and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1998;32:77-8.
14. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;1-164.
15. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-6.
16. Çukadar N, Baran F, Özsoy KE, Uyanık FB, Sürer T, Mert T et al. Nociceptive effects of locally treated metoprolol. Cukurova Medical Journal. 2015;40:258- 66.
17. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Hematol. 2001;106:148-56.
18. Nazmiye E. Vasküler endotelyal büyüme faktörü ve anti-VEGF ajanlar. Retina Vitreus. 2007;15:35-40.
19. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–1802.
20. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 1991;47:211-8.
21. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947-54.
22. Ferrara N, Houck KA, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
24. John EH. Guyton and Hall Medical Physiology. Baltimore, Elsevier, 2010.
25. Mert T, Ocal I, Gunay I. Pain relieving effects of pulsed magnetic fields in a rat model of carrageenaninduced hindpaw inflammation Int Rad Biol. 2014;95- 103.
26. Mert T, Oksuz H, Tugtag B, Kilinc M, Senoglu N, Bilgin R. Modulating actions of NMDA receptors on pronociceptive effects of locally injected remifentanil in diabetic rats. Pharmacol Rep. 2014;66:1065–1072.
27. Mert T, Gunes Y, Gunay I. Local analgesic efficacy of tramadol following intraplantar injection. Eur J Pharmacol Eur. 2007:558, 68-72.
28. Cébe SS, Zehnder-FA, BallmerHK. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006;63:601-15.
29. Noonan SA, Morrissey ME, Martin P, Biniecka M, Ó'Meachair S, Maguire A et al. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. Oncotarget. 2018;9:12,105-36.
30. Ribatti D. The inefficacy of antiangiogenic therapies. J Angiogenes Res. 2010;2:27.
31. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
33. Kong SY, Bostick RM, Flanders WD, McClellan WM, Thyagarajan B, Gross MD et al. Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev. 2014;23:545-54.
34. Arimura S, Takamura Y, Miyake S, Gozawa M, Iwasaki K, Tomomatsu T et al. The effect of triamcinolone acetonide or bevacizumab on the levels of pro-inflammatory cytokines after retinal laser photocoagulation in pigmented rabbits. Exp Eye Res. 2016;149:1-7.
35. Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J et al. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol. 2015;21:5072-80.
36. Klein A, Loewenstein A. Therapeutic monoclonal antibodies and fragments: Bevacizumab. Dev Ophthalmol. 2016;55:232-4.
37. Amoaku WMK, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye. 2015;29:9,1115.